| Title |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
|
|---|---|
| Published in |
Drug Design, Development and Therapy, December 2016
|
| DOI | 10.2147/dddt.s117080 |
| Pubmed ID | |
| Authors |
Ali T Taher, John B Porter, Antonis Kattamis, Vip Viprakasit, M Domenica Cappellini, George J Kontoghiorghes |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 12% |
| Other | 4 | 10% |
| Lecturer > Senior Lecturer | 3 | 7% |
| Student > Ph. D. Student | 3 | 7% |
| Professor | 2 | 5% |
| Other | 7 | 17% |
| Unknown | 18 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 24% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Immunology and Microbiology | 2 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 10% |
| Unknown | 20 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2017.
All research outputs
#22,778,604
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#1,757
of 2,270 outputs
Outputs of similar age
#356,800
of 416,622 outputs
Outputs of similar age from Drug Design, Development and Therapy
#34
of 42 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,622 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.